Do analysts recommend DTSQ or DYAI?

Dyadic International has a consensus price target of $3.00, indicating a potential upside of 388.52%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher earnings & valuation, DTSQ or DYAI?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Dyadic International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Dyadic International $3.09M 7.24 -$7.36M -$0.23 N/A

Dyadic International (DYAI) Competitors

$0.61 -0.03 (-3.91%)

As of 08/28/2026 04:00 PM Eastern

Compare

DYAI vs. COYA, GUTS, ANIX, DTSQ, and ONCY

Should you buy Dyadic International stock or one of its competitors? Dyadic International's main competitors and comparable companies include Coya Therapeutics (COYA), Fractyl Health (GUTS), Anixa Biosciences (ANIX), DT Cloud Star Acquisition (DTSQ), and Oncolytics Biotech (ONCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyadic International compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Dyadic International has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.54	-$21.23M	-$1.07	N/A
Dyadic International	$3.09M	7.24	-$7.36M	-$0.23	N/A

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 234.06%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 388.52%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Coya Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Dyadic International has a net margin of -201.43% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Dyadic International	-201.43%	-2,920.31%	-84.77%

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Coya Therapeutics had 14 more articles in the media than Dyadic International. MarketBeat recorded 16 mentions for Coya Therapeutics and 2 mentions for Dyadic International. Coya Therapeutics' average media sentiment score of 0.55 beat Dyadic International's score of 0.29 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
Dyadic International	Neutral

Summary

Coya Therapeutics beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Fractyl Health?

Fractyl Health (NASDAQ:GUTS) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Fractyl Health has a beta of 2.32, suggesting that its stock price is 132% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

Fractyl Health presently has a consensus target price of $5.50, indicating a potential upside of 734.60%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 388.52%. Given Fractyl Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fractyl Health is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

28.0% of Dyadic International shares are held by institutional investors. 8.5% of Fractyl Health shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Fractyl Health had 20 more articles in the media than Dyadic International. MarketBeat recorded 22 mentions for Fractyl Health and 2 mentions for Dyadic International. Dyadic International's average media sentiment score of 0.29 beat Fractyl Health's score of 0.17 indicating that Dyadic International is being referred to more favorably in the news media.

Company	Overall Sentiment
Fractyl Health	Neutral
Dyadic International	Neutral

Dyadic International has higher revenue and earnings than Fractyl Health. Dyadic International is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,165.55	-$140.95M	-$0.88	N/A
Dyadic International	$3.09M	7.24	-$7.36M	-$0.23	N/A

Fractyl Health has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Fractyl Health's return on equity of -1,362.10% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Dyadic International	-201.43%	-2,920.31%	-84.77%

Summary

Fractyl Health beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Anixa Biosciences?

Dyadic International (NASDAQ:DYAI) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

In the previous week, Anixa Biosciences had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Dyadic International. Anixa Biosciences' average media sentiment score of 0.96 beat Dyadic International's score of 0.29 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyadic International	Neutral
Anixa Biosciences	Positive

Dyadic International has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Dyadic International has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	7.24	-$7.36M	-$0.23	N/A
Anixa Biosciences	$210K	563.76	-$10.93M	-$0.31	N/A

Dyadic International currently has a consensus target price of $3.00, indicating a potential upside of 388.52%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 144.25%. Given Dyadic International's higher probable upside, equities research analysts clearly believe Dyadic International is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anixa Biosciences has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Anixa Biosciences' return on equity of -71.12% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Anixa Biosciences	N/A	-71.12%	-62.88%

28.0% of Dyadic International shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 20.9% of Dyadic International shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Anixa Biosciences beats Dyadic International on 10 of the 16 factors compared between the two stocks.

How does Dyadic International compare to DT Cloud Star Acquisition?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. DT Cloud Star Acquisition's return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Dyadic International	-201.43%	-2,920.31%	-84.77%

DT Cloud Star Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

28.0% of Dyadic International shares are owned by institutional investors. 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DT Cloud Star Acquisition has higher earnings, but lower revenue than Dyadic International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Dyadic International	$3.09M	7.24	-$7.36M	-$0.23	N/A

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Dyadic International. MarketBeat recorded 3 mentions for DT Cloud Star Acquisition and 2 mentions for Dyadic International. DT Cloud Star Acquisition's average media sentiment score of 1.07 beat Dyadic International's score of 0.29 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
DT Cloud Star Acquisition	Positive
Dyadic International	Neutral

Dyadic International has a consensus price target of $3.00, indicating a potential upside of 388.52%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts plainly believe Dyadic International is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

DT Cloud Star Acquisition and Dyadic International tied by winning 6 of the 12 factors compared between the two stocks.

How does Dyadic International compare to Oncolytics Biotech?

Dyadic International (NASDAQ:DYAI) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Dyadic International has higher revenue and earnings than Oncolytics Biotech. Dyadic International is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	7.24	-$7.36M	-$0.23	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 388.52%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 483.70%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Oncolytics Biotech has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. Oncolytics Biotech's return on equity of -2,185.97% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-201.43%	-2,920.31%	-84.77%
Oncolytics Biotech	N/A	-2,185.97%	-442.99%

In the previous week, Dyadic International and Dyadic International both had 2 articles in the media. Oncolytics Biotech's average media sentiment score of 0.35 beat Dyadic International's score of 0.29 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyadic International	Neutral
Oncolytics Biotech	Neutral

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Summary

Oncolytics Biotech beats Dyadic International on 8 of the 15 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.29M	$4.01B	$7.24B	$12.94B
Dividend Yield	N/A	3.60%	2.54%	11.02%
P/E Ratio	-2.67	11.68	273.17	25.45
Price / Sales	7.24	1,348.96	621.34	95.39
Price / Cash	N/A	110.59	79.29	54.21
Price / Book	-8.77	16.53	12.97	6.14
Net Income	-$7.36M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-11.00%	-0.30%	0.13%	-0.80%
1 Month Performance	-42.07%	11.84%	8.37%	5.56%
1 Year Performance	-33.34%	55.46%	24.55%	15.57%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.5563 of 5 stars	$0.61 -3.9%	$3.00 +388.5%	-32.3%	$23.29M	$3.09M	N/A	7	Short Interest Increase
COYA Coya Therapeutics	2.6159 of 5 stars	$4.92 +5.4%	$15.33 +211.7%	-31.6%	$109.55M	$8.02M	N/A	6	Analyst Revision
GUTS Fractyl Health	4.1836 of 5 stars	$0.72 +8.7%	$5.12 +614.0%	-33.4%	$108.24M	$90K	N/A	102	News Coverage
ANIX Anixa Biosciences	4.109 of 5 stars	$3.43 -1.7%	$8.50 +147.8%	+15.6%	$108.19M	$210K	N/A	5
DTSQ DT Cloud Star Acquisition	1.906 of 5 stars	$11.34 +0.7%	N/A	+8.6%	$100.22M	N/A	N/A	N/A	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. COYA, GUTS, ANIX, DTSQ, and ONCY

How does Dyadic International compare to Coya Therapeutics?

Summary

How does Dyadic International compare to Fractyl Health?

Summary

How does Dyadic International compare to Anixa Biosciences?

Summary

How does Dyadic International compare to DT Cloud Star Acquisition?

Summary

How does Dyadic International compare to Oncolytics Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. COYA, GUTS, ANIX, DTSQ, and ONCY

How does Dyadic International compare to Coya Therapeutics?

Which has stronger valuation and earnings, COYA or DYAI?

Do analysts rate COYA or DYAI?

Which has more risk & volatility, COYA or DYAI?

Is COYA or DYAI more profitable?

Do institutionals and insiders believe in COYA or DYAI?

Does the media favor COYA or DYAI?

Summary

How does Dyadic International compare to Fractyl Health?

Which has more volatility and risk, GUTS or DYAI?

Do analysts recommend GUTS or DYAI?

Do insiders & institutionals have more ownership in GUTS or DYAI?

Does the media refer more to GUTS or DYAI?

Which has stronger earnings and valuation, GUTS or DYAI?

Is GUTS or DYAI more profitable?

Summary

How does Dyadic International compare to Anixa Biosciences?

Does the media refer more to DYAI or ANIX?

Which has more risk and volatility, DYAI or ANIX?

Which has stronger earnings & valuation, DYAI or ANIX?

Do analysts prefer DYAI or ANIX?

Is DYAI or ANIX more profitable?

Do insiders and institutionals believe in DYAI or ANIX?

Summary

How does Dyadic International compare to DT Cloud Star Acquisition?

Is DTSQ or DYAI more profitable?

Which has more volatility & risk, DTSQ or DYAI?

Do institutionals & insiders have more ownership in DTSQ or DYAI?

Which has higher earnings & valuation, DTSQ or DYAI?

Does the media prefer DTSQ or DYAI?

Do analysts recommend DTSQ or DYAI?

Summary

How does Dyadic International compare to Oncolytics Biotech?

Which has stronger earnings & valuation, DYAI or ONCY?

Do analysts recommend DYAI or ONCY?

Is DYAI or ONCY more profitable?

Does the media favor DYAI or ONCY?

Do institutionals and insiders have more ownership in DYAI or ONCY?

Which has more risk & volatility, DYAI or ONCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools